TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present at the Cell & Gene Therapy Forum 2015, January 26 – 28, 2015 at Grand Hayatt in Washington DC, United States.

Excerpt from:
TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

Scroll to Top